Aptar Pharma, a business unit of AptarGroup, has introduced a new digital respiratory health solution called HeroTracker Sense.
Designed to transform a standard metered dose inhaler (pMDI) into a smart connected healthcare device, HeroTracker Sense is a next generation metered-dose inhaler (MDI) add-on connected device.
The device helps patients suffering from chronic respiratory diseases such as asthma, COPD, cystic fibrosis and other respiratory conditions caused by Covid-19 to track their MDI usage and improve adherence to their prescribed therapy.
HeroTracker Sense, which can be attached to the canister of an MDI, will enable asthma and COPD patients take their medication in a more informed and compliant way.
The sensors in the device allow to create and deliver information such as co-ordination of inspiration with actuation, flow rate and inhalation duration.
Through the app, other features are made available such as date and time to indicate when the patient should take their medication, in addition to environmental monitoring alerts such as temperature and humidity.
With HeroTracker Sense, healthcare providers will be able to gain valuable analytics and insights on patient training, onboarding and performance through the Aptar Pharma Cohero Health BreatheSmart connect portal.
It will allow patients to monitor their adherence through the BreatheSmart app.
Aptar Pharma digital health president Sai Shankar said: “HeroTracker Sense is a strategic addition to Aptar’s portfolio of digital health solutions in the respiratory space, and underlines Aptar Pharma’s progress in the field of digital therapeutics, as well as our commitment to providing tools that will lead to an improvement in the lives of patients.”
Developed using Aptar Digital Health’s quality management system, HeroTracker Sense is CE marked and pending FDA approval.
Aptar Pharma’s Digital Health team offers a range of digital therapeutic and patient support tools in the respiratory, oncology, diabetes, immunology, neurology, allergy and rare disease therapeutic areas.
In October last year, Stallergenes Greer collaborated with Aptar Pharma to develop a connected device and companion mobile app for the delivery of its allergen immunotherapy (AIT) treatments.
